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Abstract
Background: Alfa-Hydroxy-isocaproic acid (HICA) is an end product of leucine metabolism in human tissues such
as muscle and connective tissue. According to the clinical and experimental studies, HICA can be considered as an
anti-catabolic substance. The present study investigated the effects of HICA supplementation on body composition,
delayed onset of muscle soreness (DOMS) and physical performance of athletes during a training period.
Methods: Fifteen healthy male soccer players (age 22.1+/-3.9 yr) volunteered for the 4-week double-blind study
during an intensive training period. The subjects in the group HICA (n = 8) received 583 mg of sodium salt of
HICA (corresponding 500 mg of HICA) mixed with liquid three times a day for 4 weeks, and those in the group
PLACEBO (n = 7) received 650 mg of maltodextrin mixed with liquid three times a day for the same period.
According to a weekly training schedule, they practiced soccer 3 - 4 times a week, had strength training 1 - 2
times a week, and had one soccer game during the study. The subjects were required to keep diaries on training,
nutrition, and symptoms of DOMS. Body composition was evaluated with a dual-energy X-ray absorptiometry
(DXA) before and after the 4-week period. Muscle strength and running velocity were measured with field tests.
Results: As compared to placebo, the HICA supplementation increased significantly body weight (p < 0.005) and
whole lean body mass (p < 0.05) while fat mass remained constant. The lean body mass of lower extremities
increased by 400 g in HICA but decreased by 150 g in PLACEBO during the study. This difference between the
groups was significant (p < 0.01). The HICA supplementation decreased the whole body DOMS symptoms in the
4th week of the treatment (p < 0.05) when compared to placebo. Muscle strength and running velocity did not
differ between the groups.
Conclusion: Already a 4-week HICA supplementation of 1.5 g a day leads to small increases in muscle mass during
an intensive training period in soccer athletes.
Background
DL-a-hydroxy-isocaproic acid (HICA), also known as
leucic acid or DL-2-hydroxy-4-methylvaleric acid, is an
end product of leucine metabolism in human tissues
such as muscle and connective tissue [1,2]. Some food-
stuffs produced by fermentation, e.g. certain cheeses,
wines and soy sauce contain HICA [3-7]. According to
the clinical and experimental studies HICA can be con-
sidered as an anti-catabolic substance [8-15]. There is
an evidence of a direct in vitro inhibitory effect of HICA
on various matrix metalloproteinase enzymes, which are
responsible for degradation of various connective and
protein tissues [14]. The delayed onset of muscle
soreness (DOMS) is the sensation of muscular discom-
fort and pain during active contractions that occurs in a
delayed fashion after strenuous exercise. Subjects with
DOMS have painful, tender, and swollen muscles with
reduced range of motion of adjacent joints especially
after unaccustomed exercise [16,17]. In addition to mus-
cle tenderness with palpation, prolonged strength loss
and a reduced range of motion are observed. These
symptoms develop 24 to 48 hours after exercise, and
they disappear within 5 to 7 days [16,17]. The pathophy-
siology of DOMS remains still undetermined, but it has
been reported that after strenuous exercise muscle cell
damage and inflammatory cells are observed in damaged
muscle [16,17].
Although leucine has a unique role as a promoter of
protein synthesis [18], maybe especially the metabolites
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of leucine decrease breakdown of proteins, particularly
muscle proteins [11]. The roles and mechanisms of
actions of leucine and its metabolites are not clear and
even confusing. For instance, a-ketoisocaproate (KIC),
derived from leucine by transamination, is anti-catabolic
and reduces muscle protein degradation when given as
intravenous infusion [11]. On the other hand, it is a
potent inhibitor of branched-chain a-keto acid dehydro-
genase kinase and may lead to increased catabolism of
branched chain amino acids (BCAAs) [19]. b-Hydroxy
b-methylbutyric acid (HMB) or b-hydroxy b-methylbu-
tyrate is another metabolite of leucine and plays also a
role in protein synthesis and breakdown [20]. Recently
[21], it was observed that 14 of HMB and KIC supple-
mentation reduced signs and symptoms of exercise-
induced muscle damage in non-resistance trained males
following a single bout of resistance exercise emphasiz-
ing eccentric contractions.
There are separate mechanisms to control protein
synthesis and proteolysis [22]. Tischler et al [11] sug-
gested that the first step in controlling muscle proteoly-
sis by leucine is the oxidation of leucine, catalyzed by
aminotransferase enzyme. The end product of the reac-
tion is keto leucine (a-ketoisocaproate, KIC) but, in cer-
tain situations, it can be HICA as well. It is suggested
that the aminotransferase enzyme is responsible to oxi-
dize leucine both to its keto (KIC) and to its hydroxyl
form (HICA) and both reactions are reversible [23]. The
reaction between keto and hydroxyl leucine is an equili-
brium reaction with oxidoreduction equilibrium con-
stant (thermodynamic constant) Keq = 3.1 ± 0.2 × 10-
12 mol/l and the reaction half time is 230 min towards
oxygenation in human. Keto acid is irreversibly oxidized
by mitochondrial ketoacid dehydrogenaze [24]. Irreversi-
ble degradation of keto acids is higher in liver than that
in muscle [24]. The branched-chain a-keto acid dehy-
drogenase complex is the most important regulatory
enzyme in the catabolism of leucine [25]. The skeletal
muscle is considered to be the initial site of BCAA cata-
bolism because of its high activity of BCAA aminotrans-
ferase [2].
In our open pilot study with wrestlers [15; unpub-
lished] we assessed the effects of HICA on body compo-
sition and exercise induced DOMS. National top
wrestlers (n = 7, 79.7 ± 4.5 kg, 26 ± 6 yrs) took 0.496 g
of HICA three times per day after intensive training ses-
sions for 42 days. They had at least 10 training sessions
a week, each lasting from 1.5 to 2.5 hours. Since the
subjects were competitive athletes they had records on
their weights for years during their competition careers.
During six weeks before the HICA period there were no
essential changes in their weights. At least for the 6-
week period before and during the 42-day trial daily
diets and the number, intensity, and duration of daily
training sessions of wrestlers were kept constant.
According to DXA measurements the mean body weight
gain during the treatment period was 0.84 ± 1.0 kg (±
SD). Bone mass was not changed but total lean soft tis-
sue mass was increased statically significantly. The most
important finding of the pilot study was, however, that
subjects when using HICA did not suffer from DOMS
symptoms at all or they suffered markedly less than
before the treatment with HICA. No changes in blood
pressure, heart rate or laboratory blood values were
associated with the use of HICA suggesting that its use
is safe.
Consequently, the aim of this study was to investigate
the effects of HICA supplementation on body composi-
tion, DOMS symptoms and physical performance during
a controlled one month training period in soccer
players. Our hypothesis was that HICA would increase
total lean soft tissue mass, would decrease DOMS symp-




The subjects were fifteen healthy male soccer players
(age 22.1 ± 3.9 yr) in the local club. They signed a writ-
ten consent which was approved by the local University
Ethics Committee.
Study design
This study was a double-blind, randomized, placebo
controlled experiment. At the beginning of study the
subjects were randomized to two groups: group HICA;
n = 8, age 22.8 ± 6.4 yr, height 178.9 ± 6.8 cm, body fat
14.1 ± 3.9% and group PLACEBO; n = 7; age 21.3 ± 2.3
yr, height 178.4 ± 5.1 cm, body fat 12.5 ± 3.0%; mean ±
SD. There were no differences in baseline parameters
between the groups. The loading period with HICA or
PLACEBO lasted four weeks and the similar tests were
performed before and after the loading period. The sub-
jects were familiarized with the tests well because simi-
lar tests were used in their normal training.
Loading
The subjects in the HICA group ingested DL-a-
hydroxy-isocaproic acid (alfaHICA™ Elmomed Ltd, Hel-
sinki, Finland) and the subjects in the PLACEBO group
received maltodextrin (Manninen Nutraceuticals Ltd,
Oulu, Finland). Both supplements were powders and
three doses each were ingested per day. One HICA dose
was 583 mg as sodium salt (corresponding 500 mg of
HICA) mixed with juice or water. One PLACEBO dose
included 650 mg maltodextrin mixed also with juice or
water. Both powders were scaled and packed ready for
the subjects in 1.5 ml Eppendorf tubes. The supple-
ments were advised to ingest three times per day in
equal time intervals with meals.
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Training
Training consisted of 5-7 training sessions per week
including 3-4 soccer sessions, 1-2 resistance exercise
sessions, and one match. Resistance exercise session
included both maximal strength and speed-strength
exercises. All subjects were advised to keep training dia-
ries on which they marked all training exercises as well
as subjective evaluation of training alertness and the
morning onset of delayed muscle soreness (DOMS) in
lower and upper extremities. In both assessments the
scale was from 1 to 5 where 5 is the best training alert-
ness and the strongest soreness in the muscles. It has
been shown earlier that a correlation coefficient between
repeated measurements of muscle soreness is good (r =
0.96; [26]). Each subject was individually supervised how
to keep training diaries and to report DOMS.
Nutrition
Before the beginning of the study, each subject was
supervised to continue his normal sport nutrition pro-
gram. On the testing day the subjects were supervised
not to use any sport or dietary supplements. They were
supervised also to keep food diaries for five days in the
4-week period for what they were provided with specific
verbal and written instructions and procedures for
reporting detailed dietary intake, including how to
record portions by using household measures, exact
brand names and preparation techniques. Dietary intake
of the subjects was registered for five days including
Saturday and Sunday. The food diaries were analyzed
using the Micro Nutrica nutrient-analysis software (ver-
sion 3.11, Social Insurance Institution of Finland).
Data collection and analysis
Each subject was tested before and after the 4-week (28
days) loading period at the same time of day (Figure 1).
Blood sampling
In the morning blood samples were taken from an ante-
cubital vein in the sitting position. Two milliliters blood
from a vein was taken in K2 EDTA tubes (Terumo
Medical Co., Leuven, Belgium) for measurements of
hemoglobin and hematocrit concentration with a Sys-
mex KX 21N Analyzer (Sysmex Co., Kobe, Japan). The
intra-assay coefficient of variation (CV) was 1.5% for
hemoglobin and 2.0% for hematocrit. After the 400 m
running test (immediately, 5 min and 30 min) five milli-
liters of blood was taken in lithium-heparin tubes (Ter-
umo Medical Co., Leuven, Belgium) for measurement of
lactate (Biosen C line, Sport; EKF Magdeburg, Germany)
and pH with a Nova Biomedical STAT Profile PhOX
Plus L Analyzer (Nova Biomedical, Waltham, MA,
USA). The intra-assay CV was 3.0% for lactate and 0.1%
for pH.
Body composition
Total body composition changes were determined using
a dual-energy X-ray absorptiometry device (DXA; Lunar
Prodigy Densitometer, GE Lunar Corporation, Madison,
WI, USA). This method can differentiate total body
bone mineral density (BMD), total percentage fat, total
body tissue mass, fat mass, lean mass, bone mineral
content (BMC), and total bone calcium with CVs of
0.62, 1.89, 0.63, 2.0, 1.11, 1.10, and 1.09%, respectively
[27]
Jumping ability
Maximal standing 5-jump was used to measure explo-
siveness of leg extensor muscles in horizontal direction
[28]. Maximal vertical jumping ability was measured
using a counter movement jump (CMJ) on a contact
mat with a clock [29]. In both indoor tests the best per-
formance of three trials (recovery from 3 to 5 minutes
between the trials) was selected for the final analysis.
Running tests
Both 20 m and 400 m run were performed indoors.
Acceleration running speed was measured with a stand-
ing start over 20 m. The subject was standing 0.7 m
from the first photocell gate and then accelerated maxi-
mally over 20 m to the second photocell gate (accuracy
of 0.01s in time measurement). The fastest run of three
trials (recovery 5 minutes) was selected to the final ana-
lysis. The indoor track was 200 m on which each subject
ran alone maximally 400 m. Running times were
Figure 1 Test protocol before and after the 4-week loading period. D = DXA, RB = rest blood sample, W = standard warm up, 5J =
standing 5-jump, CMJ = counter movement jump, 20 m = 20 m sprint, B = blood sample, 400 m = 400 m run, BM = bench 1RM, BE = bench
strength endurance, SM = squat 1RM, SE = squat strength endurance.
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recorded with stopwatches by two experienced investi-
gators, and a mean performance time (accuracy of 0.1s)
was calculated for the analysis. Subjects were instructed
and verbally encouraged to give a maximal effort for the
performance.
Strength tests
Maximum strength (1RM) was measured in bench press
with a free barbell and in full squat using a Smith
machine. Strength endurance was measured performing
as many repetitions as possible using a 50% load of
1RM in both bench press and in full squat. The test
order was as follows: bench press 1RM, bench press
strength endurance, full squat 1RM, and full squat
strength endurance. Recoveries between trials were from
three to five minutes in each test and at least five min-
utes between different tests. Continuous verbal encour-
agement was given during all the test performances.
Statistical Analyses
The Analysis of Variance (A Group-by-Time Factorial
ANOVA) was used to assess statistical differences
between the treatment groups. Data were handled as
changes between the measurements before and after the
treatments. Further, bonferroni corrected paired t-test
was used to compare values before and after treatments.
P ≤ 0.05 was regarded as statistically significant. Statisti-
cal analyses were carried out using the software program
Systat for Windows (Statistics, Version 9, Evanston, IL,
USA, 1992). The results are presented as means ± SD.
Results
Training and Nutrition
There were no differences in training between the
groups of HICA and PLACEBO during the 4-week
study period. The training amount across the study per-
iod consisted of 13 ± 3 soccer sessions, 4 ± 1 strength
training sessions and 3 ± 1 matches.
The subjects ate similarly in both groups and the aver-
age daily macronutrient intake during five days across
the 4-week study period was as follows: energy 11183 ±
2361 kJ, protein 119 ± 37 g, carbohydrate 341 ± 87 g,
and fat 82 ± 23 g.
Hemoglobin and hematocrit
There were no differences in hemoglobin or hematocrit
between the groups of HICA and PLACEBO or between
before and after measurements in each group. The aver-
age value for the total subject group was 150 ± 6.4 g/l
in hemoglobin and 44 ± 0.03 in hematocrit.
Body composition
Body weight was in the HICA group before and after the
4-week study period 72.6 ± 9.1 kg and 72.9 ± 8.6 kg and in
the PLACEBO group 70.0 ± 5.2 kg and 70.1 ± 5.1 kg,
respectively. The difference between the treatments was
significant in body weight (p < 0.005), in whole lean body
mass (LBM: before 62.2 ± 6.7 and after 62.5 ± 6.5 for
HICA and before 62.2 ± 4.9 and after 62.2 ± 4.6 for PLA-
CEBO; p < 0.05; Figure 2A) while fat mass remained con-
stant. Also bone mass (3.6 ± 0.1 kg) remained constant in
both groups. The absolute changes were significant in
weight (p < 0.005) and in LBM (p < 0.05) (Figure 2B). The
difference between the treatments was significant also in
lean body mass of lower extremities (p < 0.05) (Figure 3A).
The lean body mass of lower extremities increased by 400
g in the HICA group but decreased by 150 g in the PLA-
CEBO group and the changes between the groups differed
significantly (p < 0.01) (Figure 3B). Individual changes in
relative LBM of lower extremities are presented in Figure
4. There were no differences between the groups in body
composition of upper extremities.
Performance
The performance variables are presented in Table 1.
There were no significant differences between the
groups HICA and PLACEBO in any of the variables.
DOMS and training alertness
The HICA supplementation decreased significantly (p <
0.05) the whole body DOMS symptoms only in the 4th
Figure 2 Whole lean body mass (A) and changes in whole body tissues (B). Data are mean ± SD. ## represents (p < 0.005) and #
represents (p < 0.05) difference in change between before and after measurement between the groups.
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Figure 3 Lean body mass of lower extremities (A) and the changes of its components in lower extremities (B). Data are mean ± SD. ##
represents (p < 0.001) and # represents (p < 0.01) difference in change between before and after measurement between the groups
Figure 4 Individual relative LBM changes in lower extremities. Significance between groups p < 0.05
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week of the treatment (1.4 ± 0.3) when compared to
placebo (1.8 ± 0.2) (all weeks 1.5 ± 0.3 for HICA and
1.7 ± 0.4 for PLACEBO; mean ± SD). Training alertness
was during every study week slightly better in the HICA
group (3.6 ± 0.5; 4.2 ± 0.5; 4.1 ± 0.5; 4.3 ± 0.6) com-
pared to the PLACEBO group (3.3 ± 0.6; 3.0 ± 0.9; 3.4
± 1.1; 3.4 ± 0.8) but significantly (p < 0.05) better only
in the second week.
Discussion
Main results
The 4-week supplementation with HICA increased the
whole lean body mass of the soccer players. This
increase (400 g) was emphasized in lower extremities.
Also the subjects in the HICA group felt milder DOMS
compared to the subjects in the PLACEBO group.
There were no differences between the groups in any of
the performance variables.
Body composition
The main result of this study was that lean body mass
increased with HICA during the 4-week training period.
Consequently, it is probable that skeletal muscle mass
has increased especially in the lower extremities of the
soccer players, because the main training and playing is
leg work. The precision of DXA for lean body mass is
1.11% as we mentioned in the methods. The result in
lower extremity change was small - in the HICA group
there was a mean increase of 400 g (~2%) and in PLA-
CEBO a decrease of 150 g (< 1%). Taking into account
this short duration of the experiment period the differ-
ence between the groups can be considered rather clear
(550 g). Looking also at the individual mass changes we
can see a clear difference between the groups. Only one
subject from each group is within another group.
Human skeletal muscle protein metabolism has received
significant attention over the past few decades because
of its relevance to sport, physical inactivity, aging, and
disease processes [30]. The importance of skeletal mus-
cle is obvious since it comprises about 40% of body
weight, constitutes between 50 and 75% of all proteins
[31], and is important for locomotion. However, it is
also important as an amino acid reservoir, for energy
consumption and for fuels for other tissues (e.g., brain,
immune cells). Skeletal muscle proteins have regular
turnover such that 1 - 2% of proteins are synthesized
and broken down daily [32]. The turnover of proteins
involves the ongoing processes of protein synthesis and
breakdown. A positive net protein balance occurs when
proteins accumulate in excess of their removal (e.g., fol-
lowing nutrient ingestion), whereas a negative net pro-
tein balance occurs when the breakdown of proteins
exceeds that of their synthesis (e.g., fasting). Indeed, pro-
tein, essential amino acids (particularly leucine) and
resistance exercise but also endurance exercise [33] are
powerful stimulators of skeletal muscle protein synthesis
in animal and human models [34-37] and eventually
skeletal muscle hypertrophy [18].
DL-a-hydroxy-isocaproic acid (HICA) is a physiologi-
cal agent which is normally present in the human body
in small amounts. Plasma concentration of HICA in
healthy adults is 0.25 ± 0.02 mmol/l, that of its corre-
spondent keto acid is 21.6 ± 2.1 mmol/l, and in circula-
tion HICA is not bound to plasma proteins [1]. It can
be measured from human plasma, urine and amniotic
fluid as well [38-40]. It has been earlier [41] speculated
that leucine alone accounts for about 60% of the total
effectiveness of the group of the regulatory amino acids
(leucine, tyrosine, glutamine, proline, methione, histi-
dine, and tryptophan) to inhibit the deprivation-induced
protein degradation in rat liver. The same effect is
achieved with HICA alone whereas keto acid of leucine
(a-ketoisocaproate) does not produce the same effect at
normal concentrations [41]. It seems that in the present
study the soccer players could benefit the supplementa-
tion of HICA. Their average protein intake was already
rather high, 1.6 - 1.7 g/kg/day, and the intake of HICA
per day was 1.5 g. It can be concluded that ingestion of
this extra “amino acid” HICA, even with sufficient daily
protein and thus probably also leucine intake, increases
lean muscle mass. Probably this increase comes mainly
through minimizing catabolic processes induced by
exercise but needs further studies.
It must be noticed that the training period was 4
weeks which is very short time to achieve training
effects. The training of the soccer players consisted of
resistance training (weights) only four times during 28
days whereas 13 soccer units and three matches were
Table 1 Physical performance before and after the 4-
week period
Variable HICA PLACEBO
Before After Before After
5-jump (m) 13.44 ± 0.71 13.80 ± 0.73 13.22 ± 0.70 13.63 ± 0.91
CMJ (m) 43.5 ± 0.03 42.8 ± 0.06 42.3 ± 0.06 44.2 ± 0.05
20 m (s) 3.02 ± 0.06 3.04 ± 0.11 2.96 ± 0.05 2.98 ± 0.06
400 m (s) 61.3 ± 1.8 61.7 ± 1.6 60.2 ± 1.7 59.1 ± 0.7
pH a 7.09 ± 0.11 7.17 ± 0.12 7.12 ± 0.12 7.17 ± 0.12
lactate (mmol/l) a 13.6 ± 1.3 14.5 ± 2.2 14.4 ± 2.8 14.2 ± 2.9
Bench press 1RM
(kg)
87.5 ± 21.0 87.9 ± 20.9 82.5 ± 13.5 83.3 ± 14.6
Strength
endurance (reps)
31 ± 3 32 ± 4 28 ± 2 31 ± 3
Full squat 1RM
(kg)
120 ± 19 130 ± 24 131 ± 29 138 ± 16
Strength
endurance (reps)
31 ± 8 47 ± 5 36 ± 10 38 ± 11
Data are means ± SDs. a pH is the lowest value and lactate is the highest
value after 400 m
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included. This means that a lot of endurance (both aero-
bic and anaerobic) type exercises were included and
probably catabolic processes in body were quite strong.
For this reason HICA might have been efficient in mini-
mizing those processes. The importance of making
room for protein in muscle recovery also from endur-
ance exercise in increasing mixed skeletal muscle frac-
tional synthetic rate and whole body protein balance has
been actively discussed recently [42,33].
Physical performance
There were no changes in physical performance in
either group during the 4-week period. This period was
the last month before the competitive season and the
content of the training was planned quite intensive.
Consequently, it was probably too short time period to
get strong training responses. Notwithstanding the
increase in muscle mass of the lower extremities in
HICA, full squat (1RM), 5-jump and strength endurance
in squat did not improve significantly in the HICA
group compared to the PLACEBO group. The reason
for this may be the small number of subjects and, on
the other hand, physical performance parameters
improved slightly in the PLACEBO group, too.
DOMS
The DOMS symptoms are particularly associated with
the eccentric exercise [16,17]. In soccer there are a lot
of unaccustomed movements (jumps in various situa-
tions) and motions (acceleration runs and braking after
sprint etc.) and therefore eccentric muscle functions
occur. In the present study the players marked on an
average points from 1 to 3 out of 5 showing that they
had all consistently some DOMS symptoms. During the
last 4th study week the subjects of the HICA group felt
milder symptoms compared to the subjects in the PLA-
CEBO group. Delayed presentation of the subjective
effect could be explained by enzyme inhibition. We
don’t presently know the exact mechanism of action,
but it can be speculated that decreased DOMS symp-
toms could be due to HICA’s direct inhibitory effect on
various metalloproteinase enzymes [14]. Training alert-
ness was also increased with concomitant decrease of
DOMS symptoms. That effect was significantly noted
after the 2nd week in the HICA group and thereafter it
seemed to continue up to the last weeks.
Mixture of BCAAs has recently shown to decrease
symptoms of DOMS but the most effective ratio of the
three BCAAs is unclear [43]. In our pilot study with
wrestlers [15; unpublished] the findings with HICA sug-
gested that it alone is highly effective on DOMS symp-
toms. According to literature such effect has been
described previously with the combination of a-keto iso-
caproic acid and b-hydroxy-b-methyl butyrate [21]. The
mechanism by which HICA alleviates DOMS symptoms
is unclear. Future studies are needed to compare the
effects of different leucine metabolites, leucine itself and
leucine-rich food in humans.
Conclusion
HICA supplementation of 1.5 g a day leads to small
increases in muscle mass during a four week intensive
training period in soccer athletes.
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